Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account:
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Hamburg, Germany
Anchor Academic Publishing
2014
|
| Subjects: | |
| Item Description: | Description based on online resource; title from PDF cover (ebrary, viewed April 15, 2014) |
| Physical Description: | 1 online resource (283 pages) illustrations (some color) |
| ISBN: | 9783954891870 9783954896875 |
Staff View
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044067007 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170217s2014 |||| o||u| ||||||eng d | ||
| 020 | |a 9783954891870 |c Print |9 978-3-95489-187-0 | ||
| 020 | |a 9783954896875 |c Print |9 978-3-95489-687-5 | ||
| 035 | |a (ZDB-30-PAD)EBC1640288 | ||
| 035 | |a (ZDB-89-EBL)EBL1640288 | ||
| 035 | |a (ZDB-38-EBR)ebr10856569 | ||
| 035 | |a (OCoLC)871779662 | ||
| 035 | |a (DE-599)BVBBV044067007 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 572 |2 23 | |
| 100 | 1 | |a Osmane, Malik |4 aut | |
| 245 | 1 | 0 | |a Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |c Malik Osmane |
| 264 | 1 | |a Hamburg, Germany |b Anchor Academic Publishing |c 2014 | |
| 264 | 4 | |c © 2014 | |
| 300 | |a 1 online resource (283 pages) |b illustrations (some color) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Description based on online resource; title from PDF cover (ebrary, viewed April 15, 2014) | ||
| 650 | 4 | |a Biological products | |
| 650 | 4 | |a Drugs |x Generic substitution | |
| 650 | 4 | |a Pharmaceutical biotechnology industry | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Osmane, Malik |t Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| 912 | |a ZDB-30-PAD | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029473852 | ||
Record in the Search Index
| _version_ | 1804177097562783744 |
|---|---|
| any_adam_object | |
| author | Osmane, Malik |
| author_facet | Osmane, Malik |
| author_role | aut |
| author_sort | Osmane, Malik |
| author_variant | m o mo |
| building | Verbundindex |
| bvnumber | BV044067007 |
| collection | ZDB-30-PAD |
| ctrlnum | (ZDB-30-PAD)EBC1640288 (ZDB-89-EBL)EBL1640288 (ZDB-38-EBR)ebr10856569 (OCoLC)871779662 (DE-599)BVBBV044067007 |
| dewey-full | 572 |
| dewey-hundreds | 500 - Natural sciences and mathematics |
| dewey-ones | 572 - Biochemistry |
| dewey-raw | 572 |
| dewey-search | 572 |
| dewey-sort | 3572 |
| dewey-tens | 570 - Biology |
| discipline | Biologie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01623nmm a2200385zc 4500</leader><controlfield tag="001">BV044067007</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170217s2014 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783954891870</subfield><subfield code="c">Print</subfield><subfield code="9">978-3-95489-187-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783954896875</subfield><subfield code="c">Print</subfield><subfield code="9">978-3-95489-687-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-30-PAD)EBC1640288</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-89-EBL)EBL1640288</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-38-EBR)ebr10856569</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)871779662</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044067007</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">572</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Osmane, Malik</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account</subfield><subfield code="c">Malik Osmane</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hamburg, Germany</subfield><subfield code="b">Anchor Academic Publishing</subfield><subfield code="c">2014</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (283 pages)</subfield><subfield code="b">illustrations (some color)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on online resource; title from PDF cover (ebrary, viewed April 15, 2014)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological products</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Generic substitution</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical biotechnology industry</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Osmane, Malik</subfield><subfield code="t">Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PAD</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029473852</subfield></datafield></record></collection> |
| id | DE-604.BV044067007 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:42:40Z |
| institution | BVB |
| isbn | 9783954891870 9783954896875 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029473852 |
| oclc_num | 871779662 |
| open_access_boolean | |
| physical | 1 online resource (283 pages) illustrations (some color) |
| psigel | ZDB-30-PAD |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | Anchor Academic Publishing |
| record_format | marc |
| spelling | Osmane, Malik aut Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account Malik Osmane Hamburg, Germany Anchor Academic Publishing 2014 © 2014 1 online resource (283 pages) illustrations (some color) txt rdacontent c rdamedia cr rdacarrier Description based on online resource; title from PDF cover (ebrary, viewed April 15, 2014) Biological products Drugs Generic substitution Pharmaceutical biotechnology industry Erscheint auch als Druck-Ausgabe Osmane, Malik Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| spellingShingle | Osmane, Malik Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account Biological products Drugs Generic substitution Pharmaceutical biotechnology industry |
| title | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| title_auth | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| title_exact_search | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| title_full | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account Malik Osmane |
| title_fullStr | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account Malik Osmane |
| title_full_unstemmed | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account Malik Osmane |
| title_short | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| title_sort | rift lines within european regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| topic | Biological products Drugs Generic substitution Pharmaceutical biotechnology industry |
| topic_facet | Biological products Drugs Generic substitution Pharmaceutical biotechnology industry |
| work_keys_str_mv | AT osmanemalik riftlineswithineuropeanregulatoryframeworkforbiosimilarswhentakingheterogeneityandvariationduringlifecycleofthereferencebiologicandthebiosimilarintoaccount |